**Hansa Biopharma**
Scheelevägen 22
SE-223 63 Lund, Sweden
Phone: +46 46 16 56 70

www.hansabiopharma.com

# PRESS RELEASE

# Hansa Biopharma to participate in BIO-Europe 2026

**Lund, Sweden, November 4.** Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that Renée Aguiar-Lucander, CEO, Hansa Biopharma, will participate in a panel titled "Immunology under the microscope: New frontiers" at BIO-Europe 2026, on Tuesday 10 November, at 14:00 CET, at the Koelnmesse, in Cologne, Germany.

If you are interested in meeting with Hansa's management, please contact Hansa Biopharma at ir@hansabiopharma.com.

**Event:** Panel at BIO-Europe 2026

**Title:** Immunology under the microscope: New frontiers

**Date, Time and Place:** Tuesday 10 November, 14:00 CET, Koelnmesse, Cologne, Germany

**Moderated by:** Sam Possemiers, CEO, MRM Health

**Panellists:**

- Renée Aguiar-Lucander, CEO, Hansa Biopharma
- Samuel Black, Senior Director Global Business Development, Merck KGaA
- Giulia Vestri, Partner, Claris Ventures

--- ENDS ---

**Contacts for more information:**

Adam Cutler, Chief Financial Officer
IR@hansabiopharma.com

Kerstin Falck, VP Global Corporate Affairs
media@hansabiopharma.com

**Notes to editors**

**About Hansa Biopharma**

Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company developing and commercializing novel immunomodulatory therapies to transform care for patients with acute or complex immune disorders. Hansa's proprietary IgG-cleaving enzyme technology platform addresses serious unmet medical needs in transplantation, gene therapy and autoimmune diseases. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients, and HNSA-5487, a next-generation IgG-cleaving molecule that will be developed for Guillain-Barré Syndrome (GBS). Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com and follow us on LinkedIn.

©2026 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, Idefirix®, and Idefirix flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved.